CAR-T cells and combination therapies: What's next in the immunotherapy revolution?

ABSTRACT: Cancer immunotherapies are dramatically reshaping the clinical management of oncologic patients. For many of these therapies, the guidelines for administration, monitoring, and management of associated toxicities are still being established. This is especially relevant for adoptively transferred, genetically-modified T cells, which have unique pharmacokinetic properties, due to their ability to replicate and persist long-term, following a single administration. Furthermore, in the case of CAR-T cells, the use of synthetic immune receptors may impact signaling pathways involved in T cell function and survival in unexpected ways. We, herein, comment on the most salient aspects of CAR-T cell design and clinical experience in the treatment of solid tumors. In addition, we discuss different pos

SUBMITTER: Ramello MC 

PROVIDER: S-EPMC5828987 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature